Bearer, qualified subordinated, unsecured and uncertificated notes of STUDIRACH Anstalt, Schaan. Below you will find the key terms in accordance with the securities prospectus.
The securities prospectus has been filed with the Liechtenstein Financial Market Authority (FMA) for approval. The public offer commences on the day following publication of the approved prospectus. The terms below are final; the linked prospectus is a placeholder until approval.
The gross proceeds of up to EUR 2,000,000, after deduction of issue and transaction costs, serve to finance and further develop the operating business of the issuer and the STUDIRACH Group.
Intended categories of use: advisory and project development services, staffing and recruiting projects, digitalisation, software and process development, administrative and commercial services, working capital, customer development, talent acquisition and the build-up of an appropriate liquidity reserve.
Funds may also be deployed in favour of STUDIRACH GmbH on the basis of written service, project, licence or financing agreements at arm’s-length terms. There is no fixed allocation by amount; the use of proceeds depends on the volume actually placed and operating requirements.
The following selection does not replace reading the full prospectus, in particular the section “Risk factors”.
Single document pursuant to Regulation (EU) 2017/1129 including summary, registration document, securities note and terms and conditions (Annex 1). German language.
PlaceholderPlaceholder, the approved prospectus will be published here following approval by the FMA.
The terms and conditions, the audited opening balance sheet as of 18 August 2026 including the review report of Grant Thornton AG, the group organisation chart and the commercial register extract form part of the prospectus and may be requested free of charge in writing at the issuer’s registered seat.
Subscription takes place exclusively through your custodian bank or the paying agent. STUDIRACH Anstalt does not accept subscriptions, payments or custody instructions directly.
This page is for information purposes only and constitutes neither an offer nor a solicitation of an offer to purchase or subscribe for securities, nor investment advice or a recommendation. The securities prospectus approved by the FMA Liechtenstein, including any supplements, is solely authoritative. Approval is not to be understood as an endorsement of the issuer or the securities. Investors may lose part or all of their invested capital. The notes have not been registered under the US Securities Act and may not be offered or sold in the United States or to US persons.